TICKERNERD
Menu
KPTIKPTIHealthcare · Biotechnology

KPTI Stock Forecast: Karyopharm Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.61
−0.62% on the day

The 5 Wall Street analysts covering Karyopharm Therapeutics, Inc. hold a median 12-month price target of $7.5 — +365.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 11 Sept 2026 — in the upper half.

Market cap
$36.5M
Ticker Nerd rank
55 / 100
Median analyst target
$7.50
Analysts covering
5
Revenue$33.4M−11.9% y/y
Operating income−$22.5M
Net income−$67.0M
Free cash flow−$24.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.0%
1M
−23.3%
YTD
−78.1%
1Y
−75.8%
From 52W high
−84.9%
From 52W low
0.0%
$2
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KPTI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Karyopharm Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
55 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
94
Growth
91
Size
84
Value
72
Revisions
49
Quality
42
Volatility
27
Momentum
11
Issuance
4

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KPTI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KPTI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$4$6$8$10$12Oct 25Jan 26Apr 26Jul 26KPTIHigh $11.00Median $7.50Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $3.00Median $7.50High $11.00

The green dot is the last close — the median target sits +365.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
31 July 2026HC Wainwright & Co.DowngradeNeutral$13 → $3.00
31 July 2026Piper SandlerMaintainsOverweight$16 → $7.00
6 May 2026HC Wainwright & Co.MaintainsBuy—
6 May 2026HC Wainwright & Co.MaintainsBuy$8.00 → $13
27 Apr 2026Piper SandlerReiteratesOverweight—
30 Mar 2026Piper SandlerReiteratesOverweight—
25 Mar 2026BairdMaintainsOutperform—
25 Mar 2026HC Wainwright & Co.MaintainsBuy—
10 Mar 2026Rodman & RenshawInitiatesBuy—
18 Feb 2026HC Wainwright & Co.ReiteratesBuy—
5 Feb 2026Cantor FitzgeraldInitiatesOverweight—
4 Nov 2025RBC CapitalMaintainsOutperform—
13 Oct 2025HC Wainwright & Co.UpgradeBuy—
9 Oct 2025BairdMaintainsOutperform—
9 Oct 2025Piper SandlerReiteratesOverweight—
12 Aug 2025BairdMaintainsOutperform—
16 July 2025HC Wainwright & Co.DowngradeNeutral—
11 July 2025HC Wainwright & Co.AssumesBuy$27
13 May 2025BairdMaintainsOutperform—
13 May 2025BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KPTI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KPTI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Karyopharm Therapeutics, Inc. returned −75.8% against +17.5% for the S&P 500, dividends included.

KPTI vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Oct 25Jan 26Apr 26Jul 26KPTIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KPTI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Karyopharm Therapeutics, Inc. (KPTI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 77% of US stocks

Price / sales
0.2×

Cheaper than 91% of US stocks

Price / book
−0.1×

Cheaper than 93% of US stocks

EV / EBITDA
−3.6×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
−11.9%

Higher than 14% of US stocks

Earnings growth (YoY)
−11.9%

Higher than 25% of US stocks

Gross margin
96.8%

Higher than 99% of US stocks

Operating margin
−67.4%

Higher than 16% of US stocks

Net margin
−153.3%

Higher than 4% of US stocks

Returns & dividend
Return on equity
66.9%

Higher than 94% of US stocks

Return on assets
−47.6%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Karyopharm Therapeutics, Inc. (KPTI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Karyopharm Therapeutics, Inc. has a market value of $36.5M and an enterprise value of $299.9M.

  • Revenue in the twelve months to 30 June 2026: $146.6M. The latest quarter shrank 11.9% year on year.

  • Net income over the same four quarters: −$224.7M, a −153.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−13.09.

  • Free cash flow in the twelve months to 30 June 2026: −$65.3M.

  • Shares outstanding: 22.7M.

  • Trailing P/E: −0.1×; forward P/E: −0.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Karyopharm Therapeutics, Inc. employs 228 people — $643K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

KPTI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KPTIKaryopharm Therapeutics, Inc.$36.5M
55
FLNAFilana Therapeutics, Inc.$37.3M
59
CRVOCervoMed, Inc.$38.9M
29
LITSLite Strategy, Inc.$39.6M
31
CELUCelularity, Inc.$39.9M
19
LGVNLongeveron, Inc.$32.9M
30
ALGSAligos Therapeutics, Inc.$32.3M
74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Karyopharm Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KPTI news & analysis

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRNewsWire · 1 Sept 2026neutral

Karyopharm Therapeutics announced it granted an aggregate of 1,850 restricted stock units to two newly hired employees, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants were reported in a company press release on September 1, 2026.

Why it matters — The RSU inducement grants signal the company's continued onboarding of new staff, though the size of the grants is modest and holds no immediate strategic or financial significance for shareholders.

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

PRNewsWire · 31 Aug 2026positive

Karyopharm announced it has submitted a supplemental New Drug Application to the FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for patients with myelofibrosis. The sNDA was submitted under the Accelerated Approval pathway, and Priority Review was requested.

Why it matters — This submission advances a potential new indication for XPOVIO, Karyopharm's lead commercial product, which could expand its market opportunity in myelofibrosis.

Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Karyopharm Therapeutics held its Q2 2026 earnings call, and a transcript of the event has been published by Seeking Alpha.

Why it matters — Earnings-call transcripts provide investors with management's direct commentary on quarterly financial results and business outlook.

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 13 Aug 2026negative

Karyopharm Therapeutics reported a Q2 loss of $2.32 per share, wider than the Zacks Consensus Estimate of a $1.53 loss but narrower than the $4.32 per share loss a year ago, while beating revenue estimates.

Why it matters — The wider-than-expected quarterly loss and revenue beat give KPTI watchers a current view of the company's financial performance against analyst expectations.

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

PRNewsWire · 13 Aug 2026positive

Karyopharm reported second quarter 2026 financial results, with total revenue of $33.4 million and U.S. XPOVIO (selinexor) net product revenue of $30.8 million. The company said its planned August sNDA submission for selinexor in combination with ruxolitinib in myelofibrosis under the accelerated approval pathway remains on track and reaffirmed its full-year 2026 total revenue guidance of $130 million to $150 million.

Why it matters — KPTI watchers would care because the myelofibrosis sNDA submission timing and revenue guidance confirm progress toward what could be the first approved combination therapy for myelofibrosis patients.

FAQ

Frequently asked questions about KPTI stock

What is the KPTI stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Karyopharm Therapeutics, Inc. have a median 12-month price target of $7.5, with estimates ranging from $3 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KPTI stock a buy right now?

Of the 5 analysts covering Karyopharm Therapeutics, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Karyopharm Therapeutics, Inc. 55 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KPTI?

As at 11 Sept 2026, Karyopharm Therapeutics, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

Will KPTI stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +365.8% from the last close, and Ticker Nerd's factor model ranks Karyopharm Therapeutics, Inc. 55 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KPTI stock forecast for 2030?

No analyst covering Karyopharm Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KPTI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $11 over the next 12 months.

How has KPTI stock performed over the past year?

Karyopharm Therapeutics, Inc. returned -75.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Karyopharm Therapeutics, Inc. do?

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing therapies for cancer and other serious diseases.

What is the latest news on KPTI?

The most recent item we track (PRNewsWire, 1 Sept 2026): "Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Karyopharm Therapeutics announced it granted an aggregate of 1,850 restricted stock units to two newly hired employees, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants were reported in a company press release on September 1, 2026.

Company

About Karyopharm Therapeutics, Inc.

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing therapies for cancer and other serious diseases. Karyopharm Therapeutics Inc. specializes in drugs that target nuclear export pathways, including selective inhibitor of nuclear export compounds designed to inhibit exportin 1 (XPO1). Its current portfolio centers on oncology, with marketed and late-stage programs addressing blood cancers and solid tumors. The company’s products and clinical development efforts are aimed at treating patients who need options across hematology and oncology settings, and its commercial activities support the availability of approved cancer therapies in the United States. Headquartered in Newton, Massachusetts, Karyopharm Therapeutics Inc. plays a specialized role in the biopharmaceutical market by advancing targeted treatments built around a distinct molecular mechanism.

CEO Mr. Richard A. Paulson M.B.A. · 228 employees · United States · https://www.karyopharm.com